Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 11INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 927Neoplasms 612Breast Neoplasms 611Colorectal Neoplasms 458Neoplasm Metastasis 398Ovarian Neoplasms 333Prostatic Neoplasms 316Melanoma 316Lung Neoplasms 294Multiple Myeloma 293Recurrence 281Squamous Cell Carcinoma of Head and Neck 248Stomach Neoplasms 232Pancreatic Neoplasms 231Leukemia, Myeloid, Acute 224Triple Negative Breast Neoplasms 193Endometrial Neoplasms 190Carcinoma, Renal Cell 183Lymphoma, Non-Hodgkin 178Carcinoma, Hepatocellular 178Small Cell Lung Carcinoma 166Leukemia, Lymphocytic, Chronic, B-Cell 158Advanced Solid Tumors 158Lymphoma, Follicular 150Lymphoma, Large B-Cell, Diffuse 141Urinary Bladder Neoplasms 140Lymphoma 138Advanced Solid Tumor 137Uterine Cervical Neoplasms 136Head and Neck Neoplasms 134

Interventions

Hematologic Tests 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic cancer, adult × 1 year × Clear all
NCT06717295 2026-01-02

CCANED-CIPHER

Dysplasia Diagnostics Limited

Recruiting
6,000 enrolled
CNSGastrointestinalGenitourinaryGynecologicThoracic

Pancreatic cancer, adult, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03854110 2025-09-11

Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Geistlich Pharma AG

Phase 1 Active not recruiting
64 enrolled
Gastrointestinal

Pancreatic cancer, adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡